key: cord-0866621-y0smhyg5
authors: Wang, Cheng; Wang, Shaobo; Chen, Yin; Zhao, Jianqi; Han, Songling; Zhao, Gaomei; Kang, Jing; Liu, Yong; Wang, Liting; Wang, Xiaoyang; Xu, Yang; Wang, Song; Huang, Yi; Wang, Junping; Zhao, Jinghong
title: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection
date: 2020-08-12
journal: bioRxiv
DOI: 10.1101/2020.08.12.247338
sha: 30f11689ff54b3307f2d8c914d0ee13438f5b15d
doc_id: 866621
cord_uid: y0smhyg5

The ongoing COVID-19 epidemic worldwide necessitates the development of novel effective agents against SARS-CoV-2. ACE2 is the main receptor of SARS-CoV-2 S1 protein and mediates viral entry into host cells. Herein, the membrane nanoparticles prepared from ACE2-rich cells are discovered with potent capacity to block SARS-CoV-2 infection. The membrane of human embryonic kidney-239T cell highly expressing ACE2 is screened to prepare nanoparticles. The nanomaterial termed HEK-293T-hACE2 NPs contains 265.1 ng mg−1 of ACE2 on the surface and acts as a bait to trap SARS-CoV-2 S1 in a dose-dependent manner, resulting in reduced recruitment of the viral ligand to host cells. Interestingly, SARS-CoV-2 S1 can translocate to the cytoplasm and affect the cell metabolism, which is also inhibited by HEK-293T-hACE2 NPs. Further studies reveal that HEK-293T-hACE2 NPs can efficiently suppress SARS-CoV-2 S pseudovirions entry into human proximal tubular cells and block viral infection with a low half maximal inhibitory concentration. Additionally, this biocompatible membrane nanomaterial is sufficient to block the adherence of SARS-CoV-2 D614G-S1 mutant to sensitive cells. Our study demonstrates a easy-to-acheive memrbane nano-antagonist for curbing SARS-CoV-2, which enriches the existing antiviral arsenal and provides new possibilities to treat COVID-19. Graphical Table of Contents

The attachment of SARS-CoV-2 to cell membrane is the initial step of the pathogenesis of COVID-19, in which the viral spike (S) protein that can be divided into S1 and S2 subunits after degradation by protease is attributable. 5 S1 is responsible for recognizing host receptors, while S2 mediates viral fusion into the cytoplasm. 6 Angiotensin-converting enzyme-2 (ACE2), a negative regulator of the renin-angiotensin system, is abundant in kidney, lung, and intestine. 7 SARS-CoV-2 S1 binds to ACE2 at a high affinity of 8.02 nM. 8 The cells insensitive to SARS-CoV-2 turn to be susceptible to the virus after transfection with ACE2.

Additionally, anti-ACE2 serum and human intestinal defensin able to cloak ACE2 we recently reported were efficient to inhibit SARS-CoV-2 invasion, 6, 8 indicating that ACE2 is a critical receptor for SARS-CoV-2.

Similar to that the extracellular part of the coxsackievirus and adenovirus receptor is used to inhibit Coxsackie-B-viruses, 9 recombinant human ACE2 (rhACE2) at clinical grade markedly reduces the early infection of SARS-CoV-2 and protects human blood vessel and kidney organoids. 10 Due to the natural location of ACE2 on the cell membrane, and because membrane with active ingredients are potential drug candidates, 11 we attempt to apply the membrane of human cells abundant of ACE2 to cope with SARS-CoV-2. Cell membrane-based nanoparticles (CMBNPs) are designed to overcome the shortcoming of the uneven size of membranes. Taking the advantage of functional elements on human platelet membranes, we have developed some CMBNPs with the capabilities of tumor targeting and immune escape. [12] [13] In this study, we selected the membrane of human embryonic kidney-239T cells highly expressing human ACE2 (HEK-293T-hACE2) to prepare CMBNPs after analyzing the ACE2 content in five human cells (Figure 1 ). The antiviral activity and mechanism of action of this nanomaterial were investigated by pseudovirus neutralization assay, spike adhesion experiment, and proteomics analysis. Our study demonstrates an efficient nano-antagonist that can be easily prepared in general laboratories against SARS-CoV-2, which is a feasible solution to resolve the shortage of effective measures to treat COVID-19. 

Preparation and characterization of HEK-293T-hACE2 NPs. ACE2 is rich in renal tubular epithelium, lung alveolar epithelial cells, and enterocytes of the small intestine, as revealed by immunohistochemistry and transcriptomics and proteomics analysis. 7, 14 We collected five cells including HEK-293T, HEK-293T-hACE2, human proximal tubular cell HK-2, Caco-2 enterocytes, and A549 type II pneumocytes and determined their ACE2 content by Western blot. Owing to the codon optimization, HEK-293T-hACE2 was superior to HEK-293T, Caco-2, HK-2, and A549 cells at carrying the viral receptor ( Figure 2a ).

Immunofluorescence observed that ACE2 was mostly located on the cell membrane ( Figure   2b ). HEK-293T-hACE2 cells were then selected and processed by repeated freezing and thawing to separate the membrane, which was broken by sonication and applied to fabricate CMBNPs using a classical extrusion method. 15 Transmission electron microscope (TEM) analysis revealed that similar to red blood cells (RBCs)-derived NPs prepared using the same size of polycarbonate membrane, 16 (e) Immunobloting determining the ACE2 contents in nanomaterials. β-actin is the reference. Inhibition of HEK-293T-hACE2 NPs on SARS-CoV-2 S1. SARS-CoV-2 S1 containing a receptor-binding domain (RBD) is the ligand of ACE2. 17 HEK-293T-hACE2 NPs carried abundant ACE2 (Figure 2e and 2f). Enzyme-linked immunosorbent assay (ELISA) determined that the content of ACE2 in HEK-293T-hACE2 NPs was 265.1 ng mg -1 , 3.2-fold higher than that in HEK-293T NPs (Figure 2g , P < 0.001). To evaluate the bioactivity of HEK-293T-hACE2 NPs, we initially immobilized biotinylated SARS-CoV-2 S1-RBD on Sartorius streptavidin (SA) biosensors and determined the recruitment of CMBNPs by biolayer interferometry (BLI). In line with the discrepancy in ACE2 loading, more HEK-293T-hACE2 NPs coated SARS-CoV-2 S1-RBD than HEK-293T NPs ( Figure 3a ). As SARS-CoV-2 S1 adheres to the surface of sensitive cells including HK-2, 8 we further performed a cell experiment, in which HK-2 cells were exposed to 10 μg mL -1 of SARS-CoV-2 S1.

Western blot detected that HK-2 recruited plenty of SARS-CoV-2 S1 without treatment ( Figure   3b ). Nevertheless, when the viral protein was pretreated with 2.5 mg mL -1 of CMBNPs (based on the membrane proteins), the recruitment of SARS-CoV-2 S1 was dramatically decreased.

Notably, HEK-293T-hACE2 NPs was more efficient than HEK-293T NPs at neutralizing SARS-CoV-2 S1. Binding assay further revealed that HEK-293T-hACE2 NPs interacted with SARS-CoV-2 S1-RBD in a dose-dependent manner (Figure 3c) , consistent with the results obtained by immunoblotting ( Figure S1 ). Immunofluorescence observed that SARS-CoV-2 S1 was adsorbed on HEK-293T-hACE2 NPs ( Figure 3d ) and the protein adherence was blocked by human defensin 5 (HD5, Figure S2 ), an endogenous lectin-like peptide capable of binding to and cloaking ACE2. 8 Accordingly, few viral proteins adhered to HK-2 cells after pretreatment with HEK-293T-hACE2 NPs (Figure 3e ). Immunofluorescence microscopy revealing the protection of HEK-293T-hACE2 NPs on HK-2 cells exposed to SARS-CoV-2 S1 (green). The region of interest in SARS-CoV-2 S1-treated group is magnified in the embedding graph. Nuclei are stained using DAPI (blue).

Scale bar indicates 20 μ m.

Intriguingly, SARS-CoV-2 S1 not only located on the cell membrane but in the cytoplasm of HK-2, in line with the translocation of spike in Caco-2 cells. 8 Recent multi-level proteomics analysis showed that individual proteins of SARS-CoV-2 reshaped the central pathways of host cells, causing metabolic disorders including the dysfunctions in mitochondrial translational termination and cholesterol metabolic abnormalities. 18 SARS-CoV-2 S1 might has a potential effect on cellular metabolism we speculated beyond receptor recognition. A tandem mass tags (TMT) proteomics research was then conducted to verify the conjecture. The contents of fifty-two proteins (Table S1 ) including voltage-dependent anion channel (VDAC) 1, VDAC2, and VDAC3

were significantly altered (fold-change > 1.2 ) in HK-2 cells after exposure to 100 ng mL -1 of SARS-CoV-2 S1 for 48 h (Figure 4a ). Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis discovered six signaling pathways (Table S2) , i.e., cGMP-PKG signaling pathway, NOD-like receptor signaling pathway, calcium signaling pathway, cholesterol metabolism, necroptosis, and ferroptosis, which were influenced by SARS-CoV-2 S1 (Figure 4b ). NPs to the imbalanced cell proteins induced by SARS-CoV-2 S1. VDAC1-3 are highlighted in a red frame. (d) s  e  n  c  e   a  n  d  p  r  e  s  e  n  c  e  o  f HEK-293T-hACE2 NPs. **, P < 0.01.

The up-regulation of VDAC1-3, three mitochondrial membrane porins involved in bioenergetic failure and cell apoptosis, [19] [20] were attributable. In the presence of HEK-293T-hACE2 NPs, the imbalance of VDAC1-3 was corrected (Figure 4c) , and the number of changed proteins was reduced to thirty-one (Table S3) , by which no signaling pathway was enriched by KEGG yet.

Flow cytometry revealed that 100 ng mL -1 of SARS-CoV-2 S1 increased the apoptisis of HK-2, which was significantly inhibited by 100 μg mL -1 of HEK-293T-hACE2 NPs (Figure 4d ), supporting that HEK-293T-hACE2 NPs treatment alleviates the effect of SARS-CoV-2 S1 on the metabolic process of host cells.

NPs on SARS-CoV-2 D614G-S1. Along with the viral mutation, a variant SARS-CoV-2 S1 with the Asp 614 replaced with Gly (D614G-S1) is globally prevalent. 21 The single site mutation makes SARS-CoV-2 three to nine-fold more infectious than the wild type. 22 We analyzed the molecular interaction by BLI and found that D614G-S1 bound to ACE2 at 13.3 nM (Figure 5a ), comparable to the affinity of SARS-CoV-2 S1 binding to ACE2, 8 which sustained that the stronger contagiosity of D614G-SARS-CoV-2 than its ancestral form is not due to the enhanced receptor recruitment. 23 Similarly, D614G mutation did not alter the dose-dependent bindings of HEK-293T-hACE2 NPs to SARS-CoV-2 S1 (Figure 5b ).

Immunofluorescence observed that HEK-293T-hACE2 NPs markedly lowered the adherence of D614G-S1 to HK-2 cells (Figure 5c ), indicative of the efficacy of this membrane nanomaterial at blocking mutant SARS-CoV-2. Binding kinetics for increasing concentrations of HEK-293T-hACE2 NPs and D614G-S1

loaded on SA biosensors. (c) Immunofluorescence microscopy revealing the protection of HEK-293T-hACE2 NPs on HK-2 cells exposed to D614G-S1 (green). Nuclei are stained using DAPI (blue). Scale bar indicates 20 μ m.

HEK-293T-hACE2 NPs, we employed SARS-CoV-2 S pseudovirions containing psPAX2 and luciferase reporter system to infect HK-2 cells. SARS-CoV-2 S1 binds to ACE2 and enters host cells after the proteolysis of transmembrane protease serine 2 (TMPRSS2) at the S1/S2

boundary. 24 The intracellular proprotein convertase furin also promotes SARS-CoV-2 entry by pre-activating viral spike. 25 Because human kidney is abundant of ACE2, 26 TMPRSS2, and furin ( Figure S3 ), SARS-CoV-2 S pseudovirions were largely endocytosed by HK-2 cells after a 1 h of co-incubation (Figure 6a ). HEK-293T-hACE2 NPs treatment markedly reduced viral entry, in keeping with its inhibiting effect on SARS-CoV-2 S1. TEM explained that pseudovirions were adsorbed on HEK-293T-hACE2 NPs (Figure 6b) , forming a coronavirus-like complex. 27 To determine the content of SARS-CoV-2 S1 adhered to HK-2, cells were seeded into a 6-well plate at a density of 1 × 10 6 cells/well. Recombinant SARS-CoV-2 S1 (20 were employed to detect SARS-CoV-2 S1. These experiments were repeated three times in different days.

HEK-293T-hACE2 and HK-2 cells were seeded into 12-well plates with sterile glass slides at a density of 2 × 10 5 cells/well. A total of 100 μ L of HEK-293T-hACE2 NPs (2.5 mg mL -1 , based on the membrane proteins) co-incubated with or without 10 μ g mL -1 of SARS-CoV-2 S1 at 37 °C for 1 h was dripped on sterile glass slides coated with polylysine. To observe the adherences of SARS-CoV-2 S1, D614G-S1 (40591-V08H3, Sino Biological), and pseudovirons to host cells, HK-2 was exposed to 10 

The morphologies of HEK-293T-hACE2 NPs were observed by TEM (Tecnai G2 F20   U-TWIN, FEI The location of ACE2 on HEK-293T-hACE2 NPs was observed by immunofluorescence microscopy. The exact content of ACE2 in NPs was determined with a human ACE2 ELISA kit (ab235649, Abcam, Shanghai, CHN). ELISA was conducted in triplicate and repeated three times.

The bindings of NPs to SARS-CoV-2 spike RBD (40592-V08H, Sino Biological) and D614G-S1

were measured using Forte Bio's "Octet were generated by a 1:1 fitting model.

HK-2 cells were exposed to 100 ng mL -1 of SARS-CoV-2 S1 at 37 °C for 48 h, in the absence and 

The flow cytometry was performed as we recently discribed. 13 Briefly, HK-2 was seeded in a 6-well plate at a density of 2×10 5 CFU/well and cultured overnight in DMEM containing 10%

FBS. Cells were co-incubated with 100 ng mL -1 of SARS-CoV-2 S1 for 12 h in the absence and presence of HEK-293T-hACE2 NPs (100 μg mL -1 , based on the membrane protein). The cellular apoptosis was measured with a Beyotime Annexin V / PI detection kit (C1062M) and a BD flow cytometry system (Franklin Lakes, NJ, US), in which 15,000 events per sample were obtained. The experiment was conducted in triplicate and repeated twice, and the data were processed using FlowJo software (version 7.6.1).

The adherence of SARS-CoV-2 S pseudovirons to HEK-293T-hACE2 NPs was observed with TEM, in which 40 μ L of pseudovirons (1.98 × 10 7 TU mL -1 ) were coincubated with 100 μ L of HEK-293T-hACE2 NPs (2.5 mg mL -1 , based on the concentration of membrane proteins) at 37 °C for 1 h. The luciferase assay was performed as we recently described. 8 

HUVECs obtained from the cell bank of CAS were seeded in a 96-well plate at a density of 5 × The toxicity of HEK-293T-hACE2 NPs in vivo was evaluated by a mouse experiment.

HEK-293T-hACE2 NPs (25 mg kg -1 ) were administered by intravenous injection. Mouse blood obtained through the tail vein was analyzed on a Sysmex XT-2000i fully automatic hematology analyzer (Kobe, JPN) at 1, 3, and 5 days after injection. The mice were sacrificed on day 7. HE staining and an Olympus DX51 optical microscope (Tokyo, Japan) were applied to observe the pathological changes in major organs.

The significant difference (P) between each group was calculated using SPSS 16.0 software and the LSD multiple-comparison test. A P value lower than 0.05 was defined as statistically significant.

Figures and Tables are as noted in text.

Corresponding Authors Author Contributions # C Wang, S Wang, Y Chen, and J Zhao contributed equally to this work.

The authors declare no competing financial interests. 

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Clinical features of patients infected with 2019 novel coronavirus in

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Antiviral peptides as promising therapeutic drugs

From genome to antivirals: SARS as a test tube

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Multiomics Evaluation of Gastrointestinal and Other Clinical Characteristics of COVID-19

Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2

Soluble coxsackie-and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Heat-killed Salmonella typhimurium mitigated radiation-induced lung injury

Platelet-membrane-camouflaged bismuth sulfide nanorods for synergistic radio-photothermal therapy against cancer

Irradiation pretreatment enhances the therapeutic efficacy of platelet-membrane-camouflaged antitumor nanoparticles

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

A Facile Approach to Functionalize Cell Membrane-Coated Nanoparticles

Nanoscaled red blood cells facilitate breast cancer treatment by combining photothermal/photodynamic therapy and chemotherapy

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV

VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation

VDAC2 enables BAX to mediate apoptosis and limit tumor development

SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cell entry mechanisms of SARS-CoV-2

The protein expression profile of ACE2 in human tissues

Probing the structure of the SARS coronavirus using scanning electron microscopy

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Bioengineered stem cell membrane functionalized nanocarriers for therapeutic targeting of severe hindlimb ischemia

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor